Cerebrolysin
also known as FPF 1070, porcine brain peptides
Porcine brain-derived peptide preparation containing low-molecular-weight neurotrophic peptides and free amino acids. Approved in 30+ countries for acute ischemic stroke, traumatic brain injury, and dementia. Phase 3 data in mechanical thrombectomy show improved 12-month functional independence (mRS 0-2) from 35% to 49%. Mimics endogenous neurotrophic factors (BDNF, NGF, CNTF) with multimodal neuroprotection: anti-apoptotic, anti-inflammatory, pro-neuroplastic effects.
At a glance
IV infusion · 100-250 mL saline · Daily
Primary target — Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation.
Pathway — Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis.
Downstream effect — Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery.
Origin — Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids.
Feedback intact — Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis.
| Parameter | Value |
|---|---|
| Standard dose (stroke) | 30–50 mL / day IV [staszewski-2026][afridi-2026]Most trials use 30 mL in 100-250 mL saline over 30-60 min. |
| Lower dose (dementia) | 10–20 mL / day IV or IM [khatkova-2026]Chronic neurodegenerative conditions; intermittent courses. |
| High dose (TBI) | 50 mL / day IV [kobayashi-2025]CLINCH trial protocol for intracerebral hemorrhage. |
| Duration | 10–21 days (acute); intermittent courses (chronic)Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses. |
| Timing (stroke) | Initiate within 12 hrs of symptom onset; up to 6 hrs optimalEarlier initiation associated with better outcomes. |
| Adjunct to thrombectomy | 30-50 mL daily × 10-14 days, starting day of EVTPropensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%. |
| Evidence basis | Phase 3 RCT + observational |
| Administration route | IV infusion (preferred) or IM injectionIV allows higher doses; IM used in outpatient/chronic settings. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
- — Known hypersensitivity to porcine-derived products
- — Active seizure disorder (relative — caution advised)
- — Severe renal impairment (amino acid load — monitor)
- — Pregnancy / lactation (insufficient safety data)
- 01Preparation (IV infusion)
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
- 02Infusion rate
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
- 03IM injection (alternative)
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
- 04Timing
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
- 05Storage
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
- 06Co-administration
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
Cerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
Cerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
Sources
of 65 rendered claims carry a resolvable citation.
- [afridi-2026]Afridi 2026 — Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
journal, 2026 - [kalinin-2025]Kalinin 2025 — Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: post hoc secondary analysis of the CEREHETIS trial.
journal, 2025 - [khatkova-2026]Khatkova 2026 — [Experience of using of Cerebrolysin in comprehensive rehabilitation of a patient after ischemic stroke with motor deficit and aphasia].
journal, 2026 - [kobayashi-2025]Kobayashi 2025 — Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial.
journal, 2025 - [patel-2025]Patel 2025 — Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials.
journal, 2025 - [shchulkin-2026]Shchulkin 2026 — [The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents].
journal, 2026 - [staszewski-2026]Staszewski 2026 — Cerebrolysin after Endovascular Thrombectomy in Stroke: 12‑Month Functional Outcomes in a Propensity‑Matched Cohort.
journal, 2026